ReviewInnere Medizin (Heidelberg, Germany)2026
[Sarcopenia: diagnosis, clinical implications, and treatment].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a progressive skeletal muscle disorder characterized by loss of muscle strength, muscle mass, and physical performance. Its clinical relevance is increasing with population ageing. According to the revised consensus of the European Working Group on Sarcopenia in Older People (EWGSOP2), muscle strength is central to diagnosis. The Sarcopenia Screening Questionnaire (SARC-F) and handgrip strength are suitable screening tools, while muscle mass assessed by dual-energy X‑ray absorptiometry (DEXA) or bioelectrical impedance analysis and functional tests support confirmation and severity grading. Biomarkers may complement risk stratification but do not replace functional assessment. Progressive resistance training is the most effective intervention, supported by protein intake of 1.2-1.5 g/kg body weight per day and correction of vitamin D deficiency. No specific pharmacological treatment is currently approved. Prevention includes regular physical activity, adequate nutrition, treatment of comorbidities, and early mobilisation. Sarcopenia is common, prognostically relevant, and treatable when recognised early.
Indexed as
Identifiers
42645535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.